-
Posted by
Two Blokes Jul 23 -
Filed in
Stock
-
10 views
Calgary, Alberta--(Newsfile Corp. - July 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, angina, congestive heart failure and vascular dementia, announced, further to its prior news releases dated March 5, 2025 and June 26, 2025, the closing of the sale of 15 ACP-01 Therapy Convertible Debentures for proceeds of USD $517,230, subject to the approval of the TSXV Exchange. "This is a breakthrough moment for Hemostemix," said Thomas Smeenk, CEO.
